Skip to content
Search

Latest Stories

Community pharmacy workforce is in fragile condition, says CCA report

Community pharmacy workforce is in a fragile condition and faced a shortfall of 3,000 pharmacists in England over a period of five years, a recent research conducted by the Company Chemists’ Association (CCA) has revealed.

It noted that over the last five years, the net growth of community pharmacists in England a year stood at 733. This is much lower than the required average growth of 1,025, based on data reported by the Health Education England workforce survey from 2021.


Acknowledging the discrepancies in the data calculation, the paper published by the association has used “the best available data” to highlight recent changes to the community pharmacy workforce in England.

The report noted that despite an increase in the number of pharmacists, many contractors reported an increase in pharmacist vacancies. They also reported a significant increase in locum hourly pay rates, indicating demand exceeds supply.

The CCA report highlighted other factors for workforce shortages, such as:

Changing work patterns: The report cited increased part time working, reduced working hours and portfolio working as main reasons for this condition.

The 2021 HEE workforce survey reported that average number of pharmacists by headcount per store increased to 2.43 from 1.97 in 2017, meaning on average each store had 0.46 more pharmacists. As per the CCA’s estimate, around 1,025 more pharmacists are required each year to retain equilibrium.

High vacancy rates among pharmacy support staff: The HEE 2021 workforce survey found a considerable growth in vacancies rate among support staff, which would have an impact on the workload of pharmacists.

Recruitment in Primary Care Networks (PCNs): The CCA noted that in December 2021, NHS E/I confirmed recruiting around 3,500 pharmacists into PCNs with an estimated 2,100 recruits from community pharmacy. Assuming 62 per cent of pharmacists work in community pharmacy, the CCA report estimated that around 2,385 came from the community setting.

It noted that other factors that affect the community pharmacy workforce include the growing number of non-practicing pharmacists, impact of broader portfolio working, population growth, cross border working, etc.

More For You

Mike Hewitson, superintendent pharmacist & managing director of Beaminster Pharmacy

Mike Hewitson elected as NPA board member for England

Mike Hewitson elected as NPA board member for England: New term begins April

Mike Hewitson, superintendent pharmacist & managing director ofBeaminster Pharmacy, has been elected as the next National Pharmacy Association (NPA) board member for England.

Since 2023, Hewitson has served as chair of Community Pharmacy Dorset. He is also a member of Somerset Council and a Non-Executive Director at HubRx.

Keep ReadingShow less
Store closures 2024: Chemists among hardest hit

Over 600 chemist shops belonging to multiples and chains were closed last year

Getty Images

35 shops closed per day last year, chemists worst affected

More shops are expected to exit the UK high streets driven by driven by rising operational costs and a continued shift towards online shopping and transactions.

According to figures from PwC, a total of 12,804 outlets operated by chains (those with five or more locations) exited high streets, shopping centres and retail parks in 2024 – equivalent to 35 closures per day.

Keep ReadingShow less
Empty pharmacy shelves due to UK medicine shortages.

The government has said it's investing up to £520m to manufacture more medicines

Pic credit: iStock

Brexit blamed for UK medicine shortages with "little sign of recovery"

The UK is facing “a worsening situation” with drugs shortages compared to the rest of Europe as a result of Brexit, according to the Nuffield Trust health thinktank.

It comes of the back of data that revealed that the department of health and social care (DHSC) received 1,938 notifications of disruptions to medicine supply last year – the highest in four years.

Keep ReadingShow less
Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less
PAGB welcomes new vice-presidents and treasurer to Board

Rob Elliott and Bas Vorsteveld ( L-R)

Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

PAGB appoints new vice-presidents and treasurer to Board

PAGB, the consumer healthcare association, has announced the appointment of two new vice-presidents and a treasurer to their Board.

Bas Vorsteveld, area managing director for Northern Europe at Kenvue, and Rob Elliott, OTC centre of excellence lead at Viatris, have been elected as vice-presidents.

Keep ReadingShow less